Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
WALTHAM, Mass., March 01, 2018 -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report financial results for the quarter and year ended December 31, 2017, on March 15, 2018, before the market opens.
Histogenics’ management will host a conference call on Thursday, March 15, 2018 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “7394538” five to ten minutes before the start of the call.
To access a live audio webcast of the presentation on the “Investor Relations” page of the Histogenics website, please click here. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
